What can the psychedelics industry can learn from cannabis regulation? The answer is probably “quite a bit.” Here at Harris Bricken, we’ve been thinking about this topic for a couple of years. See e.g.:
- The Psilocybin Movement is Like the Cannabis Movement (Except When It’s Not)
- Top 10 Lessons from Cannabis for the Future Regulated Psychedelics Industry
Today, as the Oregon psilocybin program ramps up, and as Colorado prepares to vote on Proposition 122 — which would legalize a host of psychedelics in Colorado — the question feels more timely than ever.
The event: What Can the Psychedelics Industry Learn from Cannabis Regulation?
On November 10, our own Vince Sliwoski will join a stellar panel convened by the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School. The full list of panelists includes:
- Hadas Alterman, Founding Partner, Plant Medicine Law Group; Founding Board Member, Psychedelic Bar Association
- Ariel Clark, Founding Partner, Clark Howell; Founding Board Member, Psychedelic Bar Association
- Robert Mikos, LaRoche Family Chair in Law, Vanderbilt Law School
- Vincent Sliwoski, Partner, Harris Bricken Sliwoski
- Moderator: Mason Marks, Florida Bar Health Law Section Professor, Florida State University College of Law; Senior Fellow, Project on Psychedelics Law and Regulation (POPLAR), Petrie-Flom Center at Harvard Law School
Event description
Here is the event description crafted by the Petrie-Flom Center:
Psychedelics have recently become a serious topic of legal reform and intense commercial investment. In the past few years, dozens of cities and states have enacted or proposed legislation to decriminalize or regulate psychedelics like psilocybin, dimethyltryptamine, mescaline, and ibogaine. Meanwhile, billions of dollars are flowing into psychedelic companies that are researching, patenting, and commercializing these substances.
For attorneys familiar with the U.S. cannabis industry, many of these developments look familiar. State cannabis markets have faced challenges associated with safety, diversity, access, and competition. This panel assembles a group of attorneys with experience in cannabis and psychedelics law to discuss what legislators, regulators, and professionals in the nascent psychedelics industry should learn from the successes and failures of cannabis regulation.
Event registration and online viewing
This will be a virtual panel discussion. To ensure access to the livestream and notification of any changes to the event, register now.
Registrants will also receive a link to the livestream the day before and day of the event. Registration closes at 11:30 a.m. on November 10. See you soon!
